ANIP
NASDAQ · Pharmaceuticals
Ani Pharmaceuticals Inc
$73.92
-0.75 (-1.00%)
Financial Highlights (FY 2026)
Revenue
696.69M
Net Income
-21,003,794
Gross Margin
59.3%
Profit Margin
-3.0%
Rev Growth
+41.7%
D/E Ratio
1.46
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 50.7% | 50.7% |
| Operating Margin | -1.1% | -1.0% | 18.0% | 18.0% |
| Profit Margin | -3.0% | -2.9% | 13.1% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 696.69M | 491.81M | 587.23M | 677.58M |
| Gross Profit | 412.93M | 291.49M | 297.61M | 343.40M |
| Operating Income | -7,802,969 | -4,957,413 | 105.58M | 122.17M |
| Net Income | -21,003,794 | -13,344,214 | 76.98M | 94.84M |
| Gross Margin | 59.3% | 59.3% | 50.7% | 50.7% |
| Operating Margin | -1.1% | -1.0% | 18.0% | 18.0% |
| Profit Margin | -3.0% | -2.9% | 13.1% | 14.0% |
| Rev Growth | +41.7% | +41.7% | +23.0% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 494.29M | 494.29M | 377.30M | 386.46M |
| Total Equity | 339.25M | 339.25M | 736.99M | 759.49M |
| D/E Ratio | 1.46 | 1.46 | 0.51 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 64.43M | 43.21M | 125.34M | 137.44M |
| Free Cash Flow | — | — | 59.62M | 74.72M |